The global Drug Discovery Informatics Market is projected to reach USD 3.5 billion in 2025 from USD 2.2 billion in 2020, at a CAGR of 9.3% during the forecast period. Market growth is largely driven by factors such as the rising R&D expenditure, growing support for research, especially in the area of rare diseases, and the increasing use of informatics in drug discovery. However, the scarcity of skilled professionals and the high setup cost of informatics software are expected to limit market growth to a certain extent.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=64537381
Browse in-depth TOC on "Drug Discovery Informatics Market”
124 – Tables
32 – Figures
140 – Pages
Key Market Players
The major companies in the drug discovery informatics market include Jubilant Life Sciences Limited (India), Charles River Laboratories (US), IBM (US), Clarivate Analytics (US), and Accenture (Ireland). These players have adopted various growth strategies such as product launches, acquisitions, to increase their presence in the global drug discovery informatics market.
Jubilant Life Sciences (India) has marked its presence among the major players in the discovery informatics market. To sustain its position in the drug discovery informatics market, the company focuses on collaborations to emerge as a preferred provider of drug discovery informatics services. For instance, in 2017, the company collaborated with Orion Corporation to provide drug discovery services. Such collaborations help the company to achieve business growth as well as advertise its expertise in the drug discovery informatics market.
Charles River Laboratories (US) offers various services ranging from target discovery to candidate validation as a part of the drug discovery informatics segment. As one of the leading firms in the industry, Charles River Laboratories has numerous strengths that help it to thrive in the marketplace. The firm also has a successful track record of integrating complimentary firms via mergers and acquisitions. It has successfully integrated a large number of technology companies in the past few years to streamline its operations and build a reliable supply chain
Inquire Before Buying this Reports:https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=64537381
This report categorizes the drug discovery informatics market into the following segments and subsegments:
By Function
- Sequencing and Target Data Analysis
- Docking
- Molecular Modelling
- Library & Database Preparation
- Other functions
By Application
- Drug Discovery
- Drug Development
By Solution
- Software
- Services
By End User
- Pharmaceutical Companies
- Biotechnology Companies
- Contract Research Organization (CROs)
Recent Developments:
- In May 2019, Jubilant selected the CDD Vault informatics platform as its discovery research informatics platform for five years
- In May, 2019, Dassault Systemes acquired Medidata Solution adding its & clinical expertise and cloud-based solutions to Dassault & portfolio
- In September 2019 Evotec collaborated with Takeda Pharmaceutical Company Limited to establish five drug discovery programs with clinical candidates from Evotec for further clinical development by Takeda across multiple therapy areas
Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=64537381
North America accounted for the largest share of the market.
The drug discovery informatics market is divided into four major regions-North America, Europe, Asia Pacific, and the Rest of the World (RoW). In 2019, North America accounted for the largest share of the global drug discovery informatics market, closely followed by Europe. The large share of North America in the global market can be attributed to the presence of well-established CROs, rising R&D expenditure by pharmaceutical and biopharmaceutical companies
The Asia Pacific is estimated to grow at the highest CAGR during the forecast period. Factors such as the rapid growth in the pharmaceutical and biopharmaceutical industry, rising number of CROs, and the presence of less-stringent regulations for drug discovery processes
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their pain points around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 Micro Quadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: [email protected]
Visit Our Website: https://www.marketsandmarkets.com/
Content Source: https://www.marketsandmarkets.com/PressReleases/drug-discovery-informatics.asp
